GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Total Assets

BRAIN Biotech AG (XTER:BNN) Total Assets : €73.25 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Total Assets?

BRAIN Biotech AG's Total Assets for the quarter that ended in Mar. 2024 was €73.25 Mil.

During the past 12 months, BRAIN Biotech AG's average Total Assets Growth Rate was -2.70% per year. During the past 3 years, the average Total Assets Growth Rate was 7.30% per year. During the past 5 years, the average Total Assets Growth Rate was 7.10% per year.

During the past 9 years, BRAIN Biotech AG's highest 3-Year average Total Assets Growth Rate was 22.00%. The lowest was 2.80%. And the median was 15.70%.

Total Assets is connected with ROA %. BRAIN Biotech AG's annualized ROA % for the quarter that ended in Mar. 2024 was -10.98%. Total Assets is also linked to Revenue through Asset Turnover. BRAIN Biotech AG's Asset Turnover for the quarter that ended in Mar. 2024 was 0.21.


BRAIN Biotech AG Total Assets Historical Data

The historical data trend for BRAIN Biotech AG's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Total Assets Chart

BRAIN Biotech AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Total Assets
Get a 7-Day Free Trial Premium Member Only 66.12 72.15 77.74 77.99 70.94

BRAIN Biotech AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.51 69.48 70.94 66.47 73.25

BRAIN Biotech AG Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

BRAIN Biotech AG's Total Assets for the fiscal year that ended in Sep. 2023 is calculated as

Total Assets=Total Equity (A: Sep. 2023 )+Total Liabilities (A: Sep. 2023 )
=23.014+47.923
=70.94

BRAIN Biotech AG's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=19.605+53.644
=73.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BRAIN Biotech AG  (XTER:BNN) Total Assets Explanation

Total Assets is connected with ROA %.

BRAIN Biotech AG's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-7.672/( (66.471+73.249)/ 2 )
=-7.672/69.86
=-10.98 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

BRAIN Biotech AG's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=14.474/( (66.471+73.249)/ 2 )
=14.474/69.86
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

BRAIN Biotech AG Total Assets Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


BRAIN Biotech AG (XTER:BNN) Business Description

Traded in Other Exchanges
Address
Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Executives
Dr. Michael Majerus Supervisory Board
Dr. Georg Kellinghusen Supervisory Board
Michael Schneiders Board of Directors
Adriaan Moelker Board of Directors
Lukas Linnig Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines